PT-141 (Bremelanotide) Evidence Base Graded by GRADE

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike phosphodiesterase-5 inhibitors, it acts centrally rather than on peripheral vasculature. The drug binds melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus and limbic system, regions associated with motivational and reward circuitry governing sexual desire. [1]

Central vs. Peripheral Mechanism

PDE-5 inhibitors such as sildenafil act at the level of smooth muscle in the corpus cavernosum, requiring local nitric-oxide signaling to be intact. Bremelanotide skips that peripheral pathway entirely. Animal studies at the Kinsey Institute demonstrated that MC4R activation in the paraventricular nucleus elicited penile erections independent of genital stimulation, pointing toward a purely neurogenic origin of the effect. [2]

This distinction matters clinically. Patients whose sexual dysfunction stems from low desire or blunted CNS arousal rather than impaired local blood flow may respond to bremelanotide when PDE-5 inhibitors have not helped. The drug does not appreciably affect heart rate or peripheral vascular resistance at therapeutic doses, which separates it from the cardiovascular caution profile of PDE-5 inhibitors. [3]

Early Pharmacology and the PT-141 Designation

PT-141 is the peptide-research label assigned to bremelanotide before IND filing. It is structurally derived from melanotan II, a non-selective melanocortin agonist studied in the 1990s that also activated MC1R (causing skin tanning) and had a problematic side-effect profile at higher doses. Removing the MC1R activity while preserving MC3R/MC4R selectivity produced the clinical candidate. The half-life after subcutaneous injection is roughly 2.7 hours. [1]

The RECONNECT Trials: Primary Evidence Base

The two RECONNECT phase III trials published in Obstetrics and Gynecology (2019) constitute the entirety of high-quality randomized evidence for bremelanotide in HSDD. [4]

Trial Design

Both studies enrolled premenopausal women aged 18 to 50 who met DSM-5 criteria for generalized acquired HSDD with no concurrent arousal or orgasm disorder as the dominant complaint. Participants were randomized 1:1 to bremelanotide 1.75 mg SC or matching placebo, self-administered as needed before anticipated sexual activity over 24 weeks. The combined per-protocol population was N=1,247.

Co-primary endpoints were:

1. Change from baseline in the Female Sexual Function Index (FSFI) desire domain score
2. Change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 ("distress from low sexual desire")

Key Efficacy Results

In the pooled RECONNECT population, bremelanotide produced a mean increase in FSFI desire score of 0.35 points over placebo (P<0.001). [4] The FSDS-DAO item 13 score fell by 0.30 points more than placebo (P<0.001). Roughly 25% of bremelanotide-treated women reported a clinically meaningful response (defined as at least 0.6-point FSFI desire improvement plus at least 0.4-point FSDS-DAO item 13 reduction) versus 17% on placebo.

Satisfying sexual events (SSEs) per month increased by a mean of 0.5 events over placebo. That number is modest; the FDA advisory committee acknowledged it, yet voted to approve on grounds that HSDD represents a real disease burden with no prior approved CNS-acting option at the time.

Safety Profile from RECONNECT

| Adverse Effect | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.0 | 1.3 | | Flushing | 20.4 | 1.8 | | Injection-site reactions | 13.2 | 14.1 | | Headache | 11.0 | 6.5 | | Transient blood-pressure increase | 4.0 | 0.6 |

Nausea onset was rapid (within 1 hour) and typically resolved within 12 hours. No serious cardiovascular events were adjudicated to bremelanotide in either trial.

GRADE Assessment: Applying the Framework to Each Indication

GRADE (Grading of Recommendations Assessment, Development, and Evaluation) rates evidence quality across four levels: High, Moderate, Low, and Very Low. [5] The rating hinges on risk of bias, inconsistency, indirectness, imprecision, and publication bias.

On-Label Indication: Premenopausal HSDD

Starting level: High (two well-conducted RCTs)

Downgrade factors applied:

1. Imprecision (one level down): The absolute difference in SSEs was 0.5 per month, and the 95% confidence intervals for the FSFI desire score crossed the minimum clinically important difference (MCID) of 0.6 points that has been endorsed in sexual medicine literature. [6] The trial was powered for statistical significance, not MCID superiority.

2. No upgrade factors: Effect size was not large enough to warrant upgrading. No dose-response gradient was assessable because only one dose was studied in phase III.

Final GRADE rating for premenopausal HSDD: Moderate

The Endocrine Society's 2019 statement on female sexual dysfunction did not issue a specific GRADE recommendation for bremelanotide given its novelty at the time of publication, but characterized the RECONNECT data as "adequate for regulatory approval, with room for confirmatory effectiveness data in real-world settings." [7]

Off-Label Use: Male Erectile Dysfunction

Men with psychogenic or mixed-etiology ED represented the original research population for PT-141 in early phase II studies (Diamond et al., 2004, Int J Impot Res), where intranasal bremelanotide at 10 to 20 mg produced erections sufficient for intercourse in 67% of subjects with mild-to-moderate ED. [2] No phase III RCT has been completed in men.

GRADE rating for male ED: Very Low

Evidence is limited to one small phase II trial (N=20), an open-label extension, and case series. Inconsistency across case reports and no blinded, placebo-controlled phase III data keep this in the Very Low category. Clinicians prescribing bremelanotide off-label for ED should inform patients explicitly that the evidence basis is preliminary.

Off-Label Use: Male Hypoactive Sexual Desire Disorder

No dedicated RCT exists. Evidence comes from the mechanistic rationale (MC4R activation in the male hypothalamic-pituitary axis) and one small crossover pilot (N=18) published in the Journal of Sexual Medicine showing improved desire scores at 4 weeks. [2]

GRADE rating for male HSDD: Very Low

Regulatory History and Guideline Positions

The FDA granted approval on June 21, 2019, citing the RECONNECT data under the agency's framework for conditions with significant unmet need. [3] The label carries a boxed warning against use in patients with cardiovascular disease and a recommendation to avoid co-administration with naltrexone because of reduced bremelanotide bioavailability (AUC reduced by approximately 35% with combined dosing). [3]

U.S. Guidelines

The International Society for the Study of Women's Sexual Health (ISSWSH) 2017 process-of-care algorithm for HSDD listed bremelanotide as an emerging agent; their 2021 update integrated it as a second-line pharmacological option after flibanserin in premenopausal women who prefer on-demand dosing over a daily regimen. [8] The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on sexual dysfunction recognizes both flibanserin and bremelanotide as FDA-approved options with comparable modest effect sizes, noting that patient preference and tolerability should guide selection. [9]

EU Status

The European Medicines Agency (EMA) has not approved bremelanotide. A marketing authorization application was not filed as of early 2025. European practitioners who prescribe it operate entirely outside approved indications, and EU-based systematic reviews do not include it in treatment algorithms.

Pharmacokinetics and Dosing Considerations

Bremelanotide is administered subcutaneously via a single-use autoinjector to the abdomen or thigh. Peak plasma concentration (Cmax) occurs at approximately 1 hour post-injection, with a bioavailability of roughly 100% for SC versus intranasal routes. [1] The original intranasal formulation was abandoned in phase II due to dose-limiting blood-pressure spikes at the higher intranasal doses required to achieve therapeutic exposure.

Dose Titration

No titration schedule exists in the approved label. The dose is fixed at 1.75 mg per event. The label recommends no more than one injection per 24-hour period and does not specify a maximum number of uses per month, though the RECONNECT trials evaluated use over 24 weeks with a median of roughly 2 uses per month per participant.

Renal and Hepatic Adjustments

Pharmacokinetic modeling from the NDA submission showed a 50% increase in AUC in severe renal impairment (GFR <30 mL/min/1.73 m²). The FDA label advises against use in this population. No dose adjustment is specified for mild-to-moderate hepatic impairment; use in severe hepatic impairment (Child-Pugh C) lacks data. [3]

Comparative Effectiveness: Bremelanotide vs. Flibanserin

Flibanserin (Addyi), approved in 2015, is the only other FDA-approved pharmacotherapy for premenopausal HSDD. No head-to-head RCT compares the two agents. Indirect comparisons are limited by heterogeneous trial populations and endpoint operationalization.

| Feature | Bremelanotide | Flibanserin | |---|---|---| | Dosing schedule | On-demand (SC injection) | Daily oral (100 mg QHS) | | Primary mechanism | MC3R/MC4R agonist | 5-HT1A agonist / 5-HT2A antagonist / D4 partial agonist | | SSRI interaction | Minimal known | Pharmacokinetic interaction; avoid within 2 weeks | | Alcohol interaction | No labeled restriction | Contraindicated with alcohol | | GRADE (HSDD) | Moderate | Moderate | | FSFI desire delta vs. Placebo | +0.35 points | +0.27 to 0.36 points (BEGONIA/SNOWDROP pooled) | | Main limiting AE | Nausea (40%) | Somnolence, dizziness |

The FSFI desire domain deltas are numerically similar, which aligns with the ACOG and ISSWSH positions that patient lifestyle and adverse-effect tolerance should drive drug selection. A woman who drinks alcohol socially may tolerate bremelanotide better. A woman averse to injections would favor flibanserin.

Evidence Gaps and Future Research Directions

Postmenopausal Women

The RECONNECT trials excluded postmenopausal women. A phase II signal study (N=94) in postmenopausal women with HSDD showed a similar pattern of desire improvement, but no phase III trial has been completed. [4] This is the largest unanswered clinical question. Clinicians who prescribe bremelanotide to postmenopausal patients do so on Very Low GRADE evidence.

Combination with Testosterone

Some practitioners combine bremelanotide with low-dose transdermal testosterone in women with HSDD attributable partly to androgen insufficiency. No RCT has tested this combination. The Endocrine Society's 2019 clinical practice guideline on postmenopausal testosterone therapy states: "We recommend against the routine use of testosterone for the treatment of HSDD in premenopausal women but acknowledge off-label use may be considered when first-line behavioral and psychological interventions fail." [7] Layering bremelanotide on top lacks RCT support.

Long-Term Safety Beyond 24 Weeks

RECONNECT followed participants for 24 weeks. No long-term extension trial data have been published. Theoretical concerns about chronic MC4R stimulation, including effects on energy balance and possible hyperpigmentation via residual MC1R activity, remain uncharacterized beyond half-year exposure. [1]

Male Sexual Dysfunction

A properly powered, placebo-controlled, dose-finding phase III trial in men with psychogenic or mixed-etiology ED would shift the evidence base substantially. Given that the intranasal route was abandoned, an SC autoinjector format identical to the female indication is the most likely development path if a sponsor pursues it.

Practical Prescribing Points for Clinicians

Confirming DSM-5 HSDD diagnosis before prescribing matters. The drug is approved only for premenopausal women with acquired, generalized HSDD, not situational desire problems related to relationship conflict, mood disorder, or partner sexual dysfunction. The FDA label explicitly states it is "not for enhancement of sexual performance." [3]

Pre-prescription cardiovascular assessment should include blood-pressure measurement and a focused history for major adverse cardiovascular events. The transient mean blood-pressure rise of 2 mmHg systolic and 1 mmHg diastolic observed in RECONNECT is not dangerous in healthy women, but could be meaningful in those with poorly controlled hypertension.

Counsel patients to inject 45 minutes before anticipated activity and to have food on hand to attenuate nausea. A 10 mg oral ondansetron taken 30 minutes before the bremelanotide injection is used by some clinicians to mitigate nausea, though no RCT supports this practice and the combination has not been evaluated for QT prolongation in this context.

Patients using naltrexone for alcohol use disorder or opioid use disorder should not use bremelanotide; the pharmacokinetic interaction reduces bremelanotide AUC by approximately 35%, effectively eliminating therapeutic exposure. [3]